|
1）Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer. J Pathol. 2011; 223: 102-15
|
|
|
|
2）Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res. 2011; 39: 6845-53
|
|
|
|
|
|
3）Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal trans-ition during tumor progression. Curr Opin Cell Biol. 2005; 17: 548-58
|
|
|
|
|
|
4）Chen X, Hu Z, Wang W, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer. 2012; 130: 1620-28
|
|
|
|
|
|
5）Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6: 2969-72
|
|
|
|
|
|
6）Yu J, Li A, Hong SM, et al. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012; 18: 981-92
|
|
|
|
|
|
7）Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008; 12: 2171-6
|
|
|
|
|
|
8）Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010; 70: 4528-38
|
|
|
|
|
|
9）Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133: 647-58
|
|
|
|
|
|
10）Lu Z, Li Y, Takwi A, et al. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 2011; 30: 57-67
|
|
|
|
|
|
11）Ling J, Kang Y, Zhao R, et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for deve-lopment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21: 105-20
|
|
|
|
|
|
12）Jiao LR, Frampton AE, Jacob J, et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One. 2012; 7: e32068
|
|
|
|
|
|
13）Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010; 24: 2754-9
|
|
|
|
|
|
14）Hamada S, Satoh K, Fujibuchi W, et al. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res. 2012; 10: 3-10
|
|
|
|
|
|
15）Feng R, Chen X, Yu Y, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010; 298: 50-63.
|
|
|
|
|
|
16）Sun Y, Bai Y, Zhang F, et al. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 2010; 391: 1483-9
|
|
|
|
|
|
17）Grutzmann R, Luttges J, Sipos B, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 2004; 90: 1053-8
|
|
|
|
|
|
18）Dorado J, Lonardo E, Miranda-Lorenzo I, et al. Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol. 2011; 46: 966-73
|
|
|
|
|
19）Hamada S, Satoh K, Hirota M, et al. The homeobox gene MSX2 determines chemo-sensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. J Cell Physiol. 2012; 227: 729-38
|
|
|
|
|
|
20）Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11: 1487-95
|
|
|
|
|
|
21）May R, Sureban SM, Lightfoot SA, et al. Iden-tification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J Physiol Gastrointest Liver Physiol. 2010; 299: G303-10
|
|
|
|
|
|
22）Sureban SM, May R, Lightfoot SA, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011; 71: 2328-38
|
|
|
|
|
|
23）Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101: 2087-92
|
|
|
|
|
|
24）Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009; 2: 807-13
|
|
|
|
|
|
25）Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011; 105: 1733-40
|
|
|
|
|
|
26）Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detec-tion of pancreatic cancer. Int J Cancer. 2012; 131: 683-91
|
|
|
|
|
|
27）Nakata K, Ohuchida K, Mizumoto K, et al. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011; 150: 916-22
|
|
|
|
|
|
28）Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011; 10: 1470-80
|
|
|
|
|